Tracked deals
4
4 tracked deals across 2026.
Public Company
Healthcare
Fagron
Nazareth, Belgium
Fagron is committed to the personalization of medicines through pharmaceutical compounding and sterile outsourcing services. It provides patient-specific medication preparation to pharmacists and prescribers, and supports hospitals, pharmacies, and patients worldwide.
- Focus Areas
- Pharmaceutical compounding, Sterile outsourcing services, Personalized patient-specific dosing
- Website
- fagron.com
Recent pace
4
4 tracked deals announced in the last 12 months.
Deal mix
Buyout
4 buyout
Fagron Acquisition Volume by Year
Last 1 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Fagron
- Target
- University Compounding Pharmacy (UCP)
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Buyout
Fagron has completed its acquisition of University Compounding Pharmacy (UCP), a California-based 503A pharmaceutical compounder focused on the health and wellness segment. The deal, initially announced in September 2025, closed following customary clearance and reinforces Fagron’s strategy to build a nationwide U.S. compounding platform spanning both 503A and 503B services.
-
January 12, 2026
- Buyer
- Fagron
- Target
- University Compounding Pharmacy (UCP)
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Buyout
Fagron has completed its acquisition of University Compounding Pharmacy (UCP), a 503A compounding pharmacy based in California and focused on health and wellness. The deal, announced in September 2025, strengthens Fagron’s U.S. footprint—particularly in California—and supports its strategy to build a nationwide platform spanning both 503A and 503B services.
-
January 6, 2026
- Buyer
- Fagron NV
- Target
- Purifarma
- Industry
- Healthcare Services
- Location
- Brazil
- Type
- Buyout
Fagron announced the completion of its acquisition of Purifarma in Brazil following CADE competition clearance in October 2025. The deal strengthens Fagron’s scalable pharmaceutical compounding platform and supports its disciplined buy-and-build strategy, with an enterprise value of approximately R$250 million.
-
January 6, 2026
- Buyer
- Fagron
- Target
- Purifarma
- Industry
- Healthcare Services
- Location
- Brazil
- Type
- Buyout
Fagron has announced the completion of its acquisition of Purifarma in Brazil, following CADE approval in October 2025. The company said the deal strengthens its scalable platform in essentials, with opportunities to improve the product mix, expand to industrial customers, and leverage purchasing advantages across Latin America.
Related Acquisition Pages
Selling a company? Get in front of buyers like Fagron
Turn tracked acquisition activity into an outreach-ready buyer list.